Skip to search formSkip to main contentSkip to account menu

alirocumab

Known as: REGN727 monoclonal antibody, monoclonal antibody REGN727 
National Institutes of Health

Related topics

Related topics

6 relations
1 ML alirocumab 75 MG/ML Prefilled Syringe1 ML alirocumab 75 MG/ML Prefilled Syringe [Praluent]Monoclonal AntibodiesPCSK9 Inhibitors [MoA]

Narrower (2)

PraluentSAR236553

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Circulating Rather Than Intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Regulates Postprandial Lipemia in Mice
Supplemental Digital Content is available in the text. Objective: Increased postprandial lipemia (PPL) is an independent risk… 
2019
2019
PCSK9-lowering RNAi contender clears first phase III trial
Review
2019
Review
2019
Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial.
Circulation. 2019;139:410–412. DOI: 10.1161/CIRCULATIONAHA.118.034993 410 In the recently presented ODYSSEY Outcomes: Evaluation… 
2017
2017
Alternative Treatment Regimens With the PCSK9 Inhibitors Alirocumab and Evolocumab: A Pharmacokinetic and Pharmacodynamic Modeling Approach
Alirocumab and evolocumab are 2 human monoclonal antibodies that inhibit the proprotein convertase subtilisin/kexin type 9 (PCSK9… 
2016
2016
Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia—Brief Report
Objective—Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors lower low-density lipoprotein (LDL) cholesterol in the… 
2016
2016
Evolocumab and alirocumab: exploring original procurement models to manage the reimbursement of these innovative treatments.
BACKGROUND PCSK9 inhibitors (evolocumab and alirocumab) pose a challenge of sustainability because the potential patients are… 
2015
2015
PCSK9 inhibitors – past, present and future
Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular disease (CVD) morbidity and mortality. Statins are… 
2015
2015
Is there enough evidence with evolocumab and alirocumab (antibodies to proprotein convertase substilisin-kexin type, PCSK9) on cardiovascular outcomes to use them widely?
Introduction: Statins alone often do not reduce LDL cholesterol levels sufficiently to given maximum cardiovascular benefit. Thus… 
2012
2012
Cholesterol-lowering blockbuster candidates speed into Phase III trials
Less than a decade on from genetic studies indicating the potential of PCSK9 as a target to affect cholesterol metabolism, two… 
2012
2012
Lipids: Antibodies against PCSK9—a new era of therapy
Antibodies against PCSK9—a new era of therapy The 2012 AHA Scientific Sessions saw considerable interest in the use of monoclonal… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)